Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-201

Date publication

juin 2024

Journal

ESMO real world data and digital oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DABAKUYO-YONLI Sandrine

Tous les auteurs :
Courtinard C, Barbet V, Schiappa R, Pilleul F, Michiels S, Dabakuyo S, Gourgou S, Jaffre A, Asselain B, Bosquet L, Dunton K, Rosenlund M, Liang Z, Cathcart J, Delaloge S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41647783

Résumé

Real-world data (RWD) can contextualize clinical trial data. We present real-world evidence that supplemented the single-arm DESTINY-Breast01 trial, which assessed the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1).

Mots clés

HER2+, T-DXd, metastatic breast cancer, propensity score-matched, real-world data

Référence

ESMO Real World Data Digit Oncol. 2024 06;4:100043